Addressing this unmet need head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease. Currently, the gold standard of treatment for OSA is CPAP therapy
Moreover, quercetin reduces leukocyte rolling and adhesion to brain microvessels, indicating its anti-inflammatory effects (Shen et al., 2019)
GLP-1 agonists, particularly tirzepatide, also cause minor increases in heart rate during the titration phase
In the chronic EAE model, MOG was utilized to induce disease in female C57BL/6 mice
It tackles severe deficiency symptoms
The Endocrine Society's Clinical Practice Guideline on pharmacological management of obesity recommends considering AOMs for patients who experience weight regain after bariatric surgery, particularly when lifestyle modifications prove insufficient